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Abstract
G protein-coupled receptors exist in a whole spectrum of conformations which are stabilised by the
binding of ligands with different efficacy or intracellular effector proteins. Here, we investigate whether
three-dimensional structures of receptor conformations in different states of activation can be utilised to
enrich ligands with agonist behaviour in prospective docking calculations. We focused on the β2-adrenergic
receptor, as it currently is the receptor with the highest number of active-state crystal structures. Compar-
ative docking calculations to distinct conformations of the receptor were used for the in silico prediction
of ligands with agonist efficacy. The pharmacology of molecules selected based on these predictions was
characterised experimentally, resulting in a hit rate of 37 % ligands, all of which were agonists. The
ligands furthermore contain a pyrazole moiety which has previously not been described for β2-adrenergic
receptor ligands and one of them shows an intrinsic efficacy comparable to salbutamol.
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Significance statement
Structure-based ligand design for G protein-coupled receptors crucially depends on receptor conformation
and hence their activation state. We explored the influence of using multiple active-conformation X-ray
structures on the hit rate of docking calculations to find novel agonists and how to predict the most fruitful
strategy to apply. The results suggest that aggregating the ranks of molecules across docking calculations to
more than one active-state structure exclusively yields agonists.
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Introduction
G protein-coupled receptors (GPCRs) are highly flexible signal transduction proteins that are embedded in
the outer membranes of eucaryotic cells. Structurally, they are relatively loose bundles of seven transmem-
brane (TM) domains that exist in a spectrum of different conformations. (Latorraca et al., 2017) Binding
of molecules that enhance signalling, i.e. agonists, to the orthosteric binding pocket (that is located within
the transmembrane core for family A GPCRs) shifts the equilibrium between the various conformations such
that binding of intracellular effector proteins (e.g. G proteins or arrestins) becomes more likely than in the
basal state of the receptor. The receptor thus becomes “activated”, and – depending on the effector – a
signalling cascade is induced.
At a structural level, the various existing X-ray structures have shown that active conformations are char-
acterised by an outward movement of the intracellular halves of TM V and VI relative to the basal state.
This is accompanied by a comparatively small contraction of the orthosteric binding pocket. (Rasmussen
et al., 2011) However, whilst binding of an agonist makes receptor-effector coupling more likely, there is also
evidence that G protein binding increases the affinity of the receptor for agonists. (De Lean et al., 1980) Re-
cently, a “reverse pharmacology” study demonstrated that extracellular agonists preferentially bind to active
receptor conformations. (Pardon et al., 2018) In this study, the β2-adrenoceptor (β2AR) was “locked” in an
active or inactive conformation through fusion with a G protein-mimicking (Nb80) or an irrelevant (Nbirr)
nanobody, respectively. Agonists bound with higher affinity to the “active” β2AR-Nb80 fusion than to the
“inactive” β2AR-Nbirr receptor fusion. For inverse agonists the opposite binding preference was detected.
Furthermore, those ligands that displayed higher affinity for the “active” conformation were confirmed to act
as agonists in subsequent cellular assays. Thus, it was possible to predict ligand efficacy from the relative
affinity to the two receptor-nanobody constructs, which correspond to different conformational ensembles.
Here, we reproduced the nanobody study in silico. It has been shown earlier that such comparative docking
calculations can increase the chance of finding molecules with agonist properties in large compound libraries
. (Weiss et al., 2013) At the same time, we have demonstrated that already small changes in receptor
structure lead to completely different ligand sets. (Kolb et al., 2012). The question thus remained whether
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the additional structures of the β2AR in active conformations that have become available in the past decade
would contain novel information and lead to different agonists. Moreover, we investigated what the best
way of aggregating the results of multiple docking calculations was. All molecules emerging from the screen
were characterised pharmacologically. In order to investigate the selectivity of the ligands’ interactions, we
performed all experiments on both the β2AR and the β1AR.
We here present the results of this study, which did not only have a remarkable overall ligand hit rate of 37 %,
but all hits were agonists. Of note, several of the newly discovered ligands feature a pyrazole moiety that has
never been described for ligands of the β2AR before. Somewhat in contrast to earlier work (Weiss et al., 2013)
and the nanobody-based assay (Pardon et al., 2018), we found that the comparison of ligand ranks between
active and inactive conformations did not lead to the highest enrichment of agonists. We therefore analysed
the retrospective enrichments of known β2AR ligands in the various conformations in order to determine
whether this behaviour can be predicted, thus allowing for appropriate choices in prospective screens.
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Materials and Methods
Primary docking screen. The crystal structures with PDB IDs 3SN6 (Rasmussen et al., 2011), 4LDL (Ring
et al., 2013) and 3NY9 (Wacker et al., 2010) were prepared for docking by protonation and subsequent min-
imisation of all hydrogen atoms with CHARMM and the CHARMm22 force field (Momany and Rone, 1992).
In addition, the binding pocket of the 3SN6 structure was relaxed by energy-minimising residues W1093.28
(numbers in superscript are according to the Ballesteros-Weinstein enumeration scheme (Ballesteros and
Weinstein, 1995)), T1103.29, D1133.32, V1173.36, F19345.52, N2936.55 and N3127.39 in presence of the ligand
visible in the crystal structure (BI-167107) to ameliorate clashes between ligand and protein, while ensur-
ing that the polar hydrogen atoms of S2075.46 and N2936.55 were pointing towards the bound ligand, thus
enabling the residues to act as hydrogen bond donors. The spheres that are used in DOCK to translate
and rotate molecules into the binding pocket were moved in order to optimise the enrichment of a set of
124 enantiomers of known β2AR ligands over decoys generated with DUD-E. (Mysinger et al., 2012) Af-
ter this optimisation step, the leads now subset of the ZINC12 library (3,687,621 molecules) (Irwin et al.,
2012) was docked to both crystal structures of the β2AR in active conformations (PDB IDs 3SN6 and 4LDL;
β2ARactive) using DOCK3.6. (Kuntz et al., 1982; Meng et al., 1992; Shoichet and Kuntz, 1993; Shoichet et al.,
1999; Mysinger and Shoichet, 2010) Besides the individual ranked lists (lists 1 and 3, Fig. 1) determined for
each docking calculation, we also generated another ranked list from the two β2ARactive dockings in order to
enrich molecules that ranked highly in the docking calculations to both structures (“dual reranking”, list 2 in
Fig. 1). Furthermore, the rank-ordered list of the docking to the β2ARactive structure 3SN6 was compared to
the list of a docking to a structure of the β2AR in an inactive conformation (PDB ID 3NY9; β2ARinactive)
to identify molecules ranked highly in an active conformation, but poorly in the inactive conformation used
in this study (“selective reranking”, list 4 in Fig. 1). Evaluation of the top 500 molecule poses in each of
the four lists (4LDL-based, 3SN6-based, dual reranking, selective reranking) was done visually in order to
manually remove molecules with artificially inflated scores due to any one of the known deficiencies of scoring
functions. (Kolb et al., 2012) For molecules that showed favourable poses but were too big to fit the binding
pocket, smaller derivatives were searched in ZINC12 and docked to 3SN6. A docking calculation to the
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β2ARinactive structure PDB ID 2RH1 (Cherezov et al., 2007) was performed to compare with our previous
docking study. (Kolb et al., 2009) This protein structure was prepared and the docking calculation conducted
in the same manner as described above. The molecules with the highest numbers of favourable interactions
in their poses from all considered ranking lists were pooled and the final list of molecules selected (for IDs
and vendors see Supplemental Table 1).
Reranking. Two ranking lists containing the same molecules docked to two different receptor structures
were compared with each other to find the highest-ranking molecules from two (dual reranking) lists or those
that ranked highly in one, but poorly in the other (selective reranking). Dual reranking was done as described
previously. (Schmidt et al., 2015) Briefly, a relative rank Rrel for each molecule is calculated for both ranking
lists using the rank r of each molecule and the total number of molecules m in the list:
Rrel,i =
ri − 1
mi − 1 (1)
where i is the indicator of each docking. With these relative ranks, a new score D is calculated for each
molecule:
D =
(Rrel,1 −Rrel,2)2 +Rrel,1 +Rrel,2
2
(2)
Molecules are then ranked according to the new score D. For further explanation on calculations see (Schmidt
et al., 2015). Dual reranking was applied to compare the docking calculations to the two structures in an
active conformation, i.e. PDB IDs 3SN6 and 4LDL.
For the selective reranking, the new score S was simply calculated as the ratio of the two ranks in the
individual dockings:
S =
r2
r1
(3)
where r1 is the molecule rank in the list of the docking calculation against 3SN6 and r2 the molecule rank in
the list of the docking calculation against 3NY9.
Similarity-based search for derivatives and structure-based evaluation. Molecules similar to lig-
ands causing the highest accumulation of cAMP in the primary cellular assay were searched in a library of
5,626,190 molecules from ZINC15 (Sterling and Irwin, 2015) using the ECFP4 fingerprint and a Tanimoto
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coefficient cutoff of ≥ 0.5. The resulting set of molecules was then docked to the structure with PDB ID
3SN6 using DOCK3.6 and molecules were selected to be tested experimentally after visual inspection of the
molecule poses as described for the primary screen (IDs and Vendors in Supplemental Table 1).
Evaluation of compound novelty. All molecules that have been tested in any way against the β2AR were
downloaded from ChEMBL (Gaulton et al., 2012) and filtered for active molecules (2374 unique entries). All
molecules that were tested within the present screen were then compared to this ChEMBL-derived dataset by
their Tanimoto similarity using ECFP4 fingerprints. (Wawer and Bajorath, 2010) To evaluate the similarity
of our ligands to any adrenergic receptor, a second dataset was prepared by downloading the bioactivity
data of all molecules targeting any one of the human adrenergic receptors from ChEMBL and filtering it for
actives (7396 unique entries). The similarity evaluation was again done using ECFP4 fingerprints and the
Tanimoto coefficent.
Cell culture. Stable cell lines of CHO cells expressing either the β2AR or β1AR and the CRE-SPAP
reporter gene were grown in Dulbecco’s modified Eagle’s medium nutrient mix F12 (DMEM/F12) containing
10% fetal calf serum and 2 mM L-glutamine at 37◦C in humidified 5% CO2:95% air atmosphere.
3H-CGP 12177 whole cell binding. Cells were plated to white 96-well plates and grown to conflu-
ence over night. Medium was then removed from the cells and replaced by 100 μL serum-free media (sfm,
DMEM/F12 containing 2 mM L-glutamine) or compound (at twice the final concentration in sfm), followed
immediately by the addition of 100 μL 3H-CGP 12177 in sfm (1:2 dilution in wells). The cells were then incu-
bated at 37◦C in humidified 5% CO2:95% air atmosphere for 2 h. After 2 h, everything was removed from all
wells and the cells were washed twice with 200 μL 4◦C phosphate-buffered saline. Microscint 20 (100 μL) was
added to each well and the plates were left at room temperature in the dark for several hours before being
counted on a TopCount. (Baker, 2005) Propranolol (10 μM) was used to define non-specific binding in all
plates and the final concentration of 3H-CGP 12177 was 0.5-0.9 nM. All compounds were examined in 7-point
concentration response curves with each condition repeated in triplicate in each experiment. A sigmoidal
curve was fitted to the data using Graphpad Prism 7 and an IC50 determined from the following equation.
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% specific binding = 100− 100
1 + 10(log(IC50)−log[A])
(4)
where [A] is the concentration of the competing ligand and IC50 is the concentration at which half of the
specific binding of 3H-CGP 12177 has been inhibited.
From the IC50 value and the known concentration of radioligand, [
3H-CGP 12177], a KD value (concentration
at which half the receptors are bound) was calculated using the Cheng–Prusoff equation:
KD =
IC50
1 + [
3H−CGP 12177]
KD(3H−CGP 12177)
(5)
The KD of
3H-CGP 12177 in these cells was 0.42 nM for the β1AR and 0.17 nM for the β2AR. (Baker, 2005)
CRE-SPAP production. Cells were plated to clear 96-well plates and grown to confluence overnight.
Media was then removed from all wells and replaced with 100 μL sfm for 24 h (i.e. cells were serum starved).
The following day, media was again removed and replaced by 100 μL fresh sfm. Where used, antagonists
diluted in sfm were used instead of pure sfm. Compound (10 μL diluted in sfm) was then added to the wells
and the cells incubated for 5 h at 37◦C and humidified 5% CO2:95% air atmosphere. After 5 h, everything was
removed from all wells and replaced by 40 μL sfm. Cells were then incubated for 1 h at 37◦C and humidified
5% CO2:95% air atmosphere before being placed in a 65
◦C oven for 30 min. The plates were cooled to room
temperature and 100 μL of 5 mM para-Nitrophenylphosphate in DEA buffer (1 M diethanolamine, 0.28 M
NaCl, 0.5 mM MgCl2, pH 9.85) added to each well. Once the yellow colour had developed, plates were
read on an MRX plate reader through a 405 nm filter. (Baker et al., 2014) Isoprenaline (10 μM) was used
as a positive control in all plates. All compounds were examined as a 7-point concentration-response with
triplicate condition for each concentration of ligand. A sigmoidal concentration response curve was fitted to
the data using GraphPad Prism 7 (eq. 6).
Response =
Emax
1 + 10(log(EC50)−log[A])
(6)
where Emax is the maximum response, [A] is the agonist concentration and EC50 is the concentration of
agonist that produces 50% of the maximal response.
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To prove that the agonist responses were indeed occurring via the transfected βAR, the affinity (log KD
value) of CGP 20712A or ICI 118551 was calculated from the rightward shift of the agonist concentration
responses in the presence of a fixed concentration of antagonist using the Gaddum equation:
DR = 1 +
[B]
KD
(7)
where DR (dose ratio) is the ratio of the agonist concentration required to stimulate an identical response in
the presence and absence of the fixed concentration of antagonist [B].
Efficacy ratios. As the affinity (KD) and potency of the agonist response (EC50) for each ligand were
determined in the same cell lines and ligands were all examined in parallel experiments, an indicator of
intrinsic efficacy (ability of a compound to stimulate a response) can be determined from the efficacy ratio
(KD/EC50) at each receptor. This therefore takes into account the affinity of the ligand, and although the
score cannot be compared across cell lines, it can be used to rank ligands in order of intrinsic efficacy at each
receptor. Thus cimaterol, with a β2AR affinity (KD) of 81 nM and a β2AR EC50 value of 0.21 nM, is very
efficacious as it hardly needs to occupy any receptors in order to stimulate a maximum response (efficacy
ratio of 386). At the same receptor, salmeterol, although of higher affinity (KD 0.81 nM, EC50 0.012 nM),
once bound, is less efficacious (efficacy ratio 67). CGP 12177 is a partial agonist (as can be seen from the 37%
stimulation in relation to isoprenaline). As a partial agonist, it needs to occupy all of the available receptors
to stimulate its maximum 37% response, and the KD value (0.28 nM) and EC50 value (0.19 nM) are similar,
giving a low efficacy ratio of 1.47.
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Results
Primary docking screen. The leads now subset of the ZINC12 library (Irwin et al., 2012) consisting
of 3,687,621 molecules was docked to two β2ARactive (PDB IDs 3SN6 and 4LDL)). As described in the
Methods, four different schemes were used to rank the molecules from the docking calculations (detailed in
Fig. 1). Molecules were ranked individually in both conformations (list 1 [red] and list 3 [yellow] in Fig. 1) and
re-ranked to identify consistently favourably ranked molecules (list 2 [orange] in Fig. 1) as well as those that
had a large difference in ranks when compared to the docking to a β2ARinactive (PDB ID 3NY9; list 4 [green] in
Fig. 1). In each of these four ranking schemes, the top 500 molecules were visually inspected in order to remove
molecules that are ranked highly because of insufficient punishment of unfavourable interactions due to the
known deficiences of current force fields. From the first three rankings (docking calculations to the β2ARactive;
lists 1, 2, and 3 [red, orange, and yellow, respectively] in Fig. 1), 18 molecules were selected and purchased
for testing. Five additional molecules showed favourable poses in the orthosteric pocket, but had several
parts protruding beyond it, and these parts consequently did not entertain favourable interactions. Smaller
derivatives of these molecules were therefore searched in ZINC12, with the aim to keep the key interacting
parts constant and only changing the bulky non-interacting moieties. The nine resulting derivative molecules
were docked to the 3SN6 structure, poses were evaluated visually and three of the smaller derivatives were
selected to be tested (pink box, Fig. 1). The parent molecules of these three derivatives emerged from the
dual reranking (3SN6 vs. 4LDL; one derivative) and the selective reranking (3SN6 vs. 3NY9; two derivatives),
respectively. Interestingly, ranking 4, contrasting the results from a docking calculation to a β2ARinactive and
a β2ARactive, did not yield any molecules that were deemed worth testing after visual inspection.
One additional molecule was selected from a separate docking calculation to the β2ARinactive structure with
PDB ID 2RH1 (list 6 [darker blue] in Fig. 1), which we had done to compare with our earlier study. (Kolb
et al., 2009) Molecule 8 was chosen because of its pose in the β2ARinactive, which featured interactions with
D1133.32. Interestingly, this molecules did not feature the same docking pose in the various β2ARactive docking
calculations because the bulky substituent of 8 forced a flipped pose in the pocket. Nonetheless, we decided
to evaluate it as a possible agonist because of its significantly smaller size, which is generally considered to
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be one of the hallmarks of β2AR agonists.
Similarity-based search for derivatives of the initial hits and structure-based evaluation. An
initial evaluation of the compounds in a cAMP-accumulation-based assay in HEK293T cells (Results in
Supplemental Data, Supplemental Fig. 1) revealed two ligands with a higher-than-average percentage of
activation, 1 and 2. These two molecules are close analogs of each other. A similarity search with these
molecules as query retrieved 62 additional molecules. Since the parent molecules had the highest ranks in the
docking calculation using β2ARactive structure 3SN6, the derivatives were docked to the same structure to
evaluate their steric fit. A complementary docking to the β2ARinactive structure 3NY9 was used to compare
the docking poses and validate them. Based on their favourable poses, five molecules were selected for detailed
pharmacological analysis (salmon box in Fig. 1).
Pharmacological characterisation. A total of 27 molecules (22 from the primary docking screen and
5 from the similarity-based search) were examined in CHO cells stably expressing either the human β2AR
(CHO-β2) or the human β1AR (CHO-β1).
Ligand affinity was determined from a whole cell 3H-CGP 12177 radioligand displacement assay. CGP 20712A,
a known β1AR-antagonist, bound to the β2AR with much lower affinity than the β1AR (log KD -5.8 and -8.6,
respectively), whilst ICI 118551 bound to the β2AR with higher affinity (log KD -9.3 at the β2AR, -6.8 at the
β1AR), thus demonstrating the presence of the two receptors in the respective cell lines (Table 1). Of the 27
ligands examined, ten were found to have measureable affinity, eight from the primary screen and two from
the similarity-based search. A further six molecules had very low affinity such that the calculation of KD
values was not possible. The compound with the highest affinity was 1 with an affinity for both the β2AR
and the β1AR of around 520 nM (Table 1, Fig. 2).
The ability of compounds to stimulate a functional response was then examined in the same cells using
the CRE-SPAP reporter stably expressed in both cell lines. The benefit of this system is that it is an
amplified downstream readout, thus maximising the chances of detecting any agonist properties. (Baker
et al., 2004) Given that partial agonists may be amplified to appear more like full agonists in this system,
several well-known partial agonists were included in the study for comparative purposes. Cimaterol, a
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relatively nonselective βAR agonist, stimulated a full agonist response with respect to isoprenaline in both
cell lines (logEC50 -9.7 at the β2AR, logEC50 -8.6 at the β1AR, Table 2). As expected, denopamine, a known
β1AR-selective agonist, stimulated a full agonist response that was more potent in the β1AR cell line, whilst
salbutamol, a known β2AR-selective agonist, was more potent in the β2AR cell line (Baker, 2010) (Table 2).
As anticipated, the 17 compounds with no affinity in the binding assay were also not able to stimulate any
significant agonist response in either cell line. These compounds therefore did not interact with either the
β2AR or β1AR.
Of the ten compounds that did have measureable affinity, all showed agonist efficacy (Table 2, Fig. 2) and
1 was the most potent ligand at both receptors. However, it was important to be sure that these agonist
responses were indeed occurring via the transfected receptors. Dose responses were therefore examined in the
parent CHO-CRE-SPAP cells that contain the stably transfected reporter gene but no transfected receptor.
No agonist responses were elicited by any of the ten novel agonist compounds, nor by cimaterol, denopamine,
salbutamol, salmeterol or CGP 12177, in CHO-CRE-SPAP cells (n=3 for each ligand).
Finally, the agonist responses were inhibited by the selective antagonists CGP 20712A and ICI 118551 in their
respective cell lines. In the CHO-β2 cells, agonist responses to cimaterol, salbutamol, salmeterol, denopamine
and CGP 12177 inhibited by ICI 118551 yielded very similar log KD values (approximately log KD -9.6, and
similar to the log KD value of ICI 118551 (-9.3) determined from the binding assay, Table 1, 2). Similar
high affinity values for ICI 118551 were obtained from its ability to inhibit the agonist responses to the ten
novel compounds (Table 2). This suggests that all these ligands were acting via the orthosteric pocket of
the transfected β2AR, its orthosteric pocket and the same receptor conformation. Compound 8 stimulated a
partial agonist response in the CHO-β2 cells, and although it was inhibited by ICI 118551, a right-ward shift
and flattening of the curve was observed. As such, the dose-response curve did not reach the same maximum
in the presence of ICI 118551 and thus a log KD could not be calculated using the Gaddum equation.
The β1AR exists in at least two conformations: a high-affinity catecholamine conformation (where responses
are readily inhibited by antagonists) and a low-affinity secondary conformation (where inhibition of agonist
responses requires much higher concentrations of antagonist) where CGP 12177 is an agonist. (Konkar et al.,
2000; Granneman, 2001) In the CHO-β1 cells, agonist responses to cimaterol, salbutamol, salmeterol and
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denopamine were inhibited by CGP 20712A to yield high affinity values for CGP 20712A, again similar to
those seen from the binding assay (Table 1, 2). The agonist response to CGP 12177, however, required
significantly higher concentrations of CGP 20712A to achieve a right-ward shift, and thus yielded a log KD
value for CGP 20712A much lower than that of the other compounds (Table 2). This is because the agonist
response to CGP 12177 is occurring via the secondary conformation. (Baker, 2005) The agonist responses to
the novel compounds were all inhibited by CGP 20712A to yield values very similar to those for the literature
compounds, and similar to those obtained in the binding assay. All of these compounds are therefore exerting
their agonist action through the orthosteric pocket in the primary catecholamine conformation of the β1AR.
Perhaps not surprisingly, as this is the conformation most similar to that of the β2AR.
Hit rates. In total, we tested 27 molecules, 22 emanating from the primary docking screen and 5 from the
similarity-based search. The competition binding assay confirmed 10 new ligands of these 27 tested molecules,
corresponding to a hit rate of 37 % (see Table 1, Supplemental Table 2) . All of the 10 compounds showed
agonistic activity, i.e. again a 37% overall hit rate or 100% of the discovered ligands (Table 2). Two of these
novel agonists resulted from the similarity-based search (i.e. 2 of 5 molecules, a 40% hit rate). Only 1 of the 22
molecules from the primary screen was retrieved from the docking calculation to the inactive receptor 2RH1
(5%). The majority of discovered agonists, 7, originated from the dual reranking (7/22 molecules; 32%). The
overall hit rate of 37 % is at the upper end compared to other docking studies using the β2AR (Sabio et al.,
2008; Kolb et al., 2009; Weiss et al., 2013; Schmidt et al., 2017; Chevillard et al., 2019) or related aminergic
GPCRs (Carlsson et al., 2011; Kruse et al., 2013).
Correlation between retrospective ligand enrichments and hit rates. The rather large variation
in the number of ligands retrieved from the five docking and reranking schemes made us wonder whether
this could have been predicted. To that end, we applied the ranking schemes to the set of 124 known active
enantiomers and their decoys that had originally been used to optimise the docking procedure. For each
of the resulting ranking lists we calculated receiver operating characteristic (ROC) plots. These plots allow
assessment of the enrichment of agonists and antagonists in the top ranks versus the decoy molecules in
each of the docking schemes. Agonists are enriched to a similar extent in each of the docking calculations
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to a β2ARactive as well as in both reranked lists and also better than antagonists (Fig. 3, Supplemental Fig.
2). Furthermore, selective reranking leads to below-random enrichment of antagonists, albeit with an early
enrichment similar as in the docking calculations to the two β2ARactive structures.
Interestingly, although overall enrichment of agonists and antagonists in the ranking lists of the dual reranking
does not differ noticably from the other three ranking schemes, antagonists are only enriched after roughly
6 % of the decoys have been found. For a set of 3.6 million molecules (such as the one we used here) this would
mean that no antagonists appear in the top 200,000 molecules of the dual reranking list and, therefore, all
hits from the top 200,000 should be agonists. While this is certainly overestimating the results, this reasoning
is in line with the hit rate achieved during the large library docking screen.
Ligand novelty. Novelty of the discovered ligands was evaluated by comparison to all compounds binding
to or acting at the β2AR or any adrenergic receptor according to ChEMBL. (Gaulton et al., 2012) While
the most active novel agonist discovered during this screen, compound 1, is similar to known βAR agonists
in that it contains a β-hydroxy-amine, it also contains a pyrazole moiety, a feature it shares with six of
the novel agonists discovered in the primary docking screen. Molecules featuring this moiety have so far
never been described as ligands of the β2AR. Because of this unprecedented ring, the ligands have relatively
low Tanimoto similarity values compared to known β2AR ligands in ChEMBL (Gaulton et al., 2012). The
highest similarity value was 0.47 (8 to CHEMBL599896) and only four molecules showed a similarity > 0.4
(see Supplemental Table 3). None of the most similar compounds contained the same structural motifs as
the query molecules.
The more general comparison against ligands of any adrenergic receptor revealed a similar picture. The
highest similarity was 0.49 (low affinity 14 to CHEMBL15303) or 0.47 (8 to CHEMBL599896) within this
search. Matches with a similarity > 0.4 were found for only seven of the molecules (see Supplemental Table
4). Casting an even wider net, all compounds containing the basic substructure of phenyl, β-hydroxy-amine
and pyrazole where retrieved from ChEMBL. None of them was associated with bioactivity data for the
β2AR. We note that compound 7 has previously been described as a weak κ-opioid receptor antagonist
(pKi = 5.19) (Zheng et al., 2017), but never as a β2AR ligand. (Wawer and Bajorath, 2010)
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Predicted binding poses. In the predicted docking pose, the β-hydroxy-amine of 1 interacts with D1133.32
and N3127.39 (Fig. 4A). The fluorine substituent in ortho position on the aromatic moiety might contribute
interactions with the protein (potentially N2936.55 or Y3087.35 in the β2AR) that explain its affinity and
agonistic activity.
Compound 8 stands out from the other tested molecules since it is the only one that was dicovered from a
docking calculation to a β2ARinactive. This molecule has a bulkier structure than the other ligands, with an
aliphatic chain and an additional aromatic moiety attached to the more standard benzene ring following the
β-hydroxy-amine. Of note, besides the weak H-bond acceptor ether oxygen, there is no other possibility to
interact with any of the Ser residues in TM V. In the larger binding pocket of the β2ARinactive, compound 8
is predicted to adopt a pose with the alkyl-aromatic moiety pointing towards ECL2 (Fig. 4B). Unexpectedly,
this molecule pose could not be reproduced in a docking calculation to the narrower β2ARactive binding
pocket. It is interesting to mention that this molecule has only slightly lower affinity (1 μM at the β2AR)
than the highest-affinity agonist 1. One potential reason for its counterintuitive binding preference might be
that it is only a partial agonist at the β2AR (with a response of 35% that of isoprenaline and very similar
to that of CGP 12177 at 37%). As expected for a partial agonist, the efficacy ratio is low. Despite the large
difference in affinity of 8 and CGP 12177 (Table 1), once bound, both compounds have a similar ability to
activate the receptor (i.e. have similar intrinsic efficacy, as demonstrated by the efficacy ratio). Given that
the CRE-SPAP response is an amplified system, (Baker et al., 2004) 8 can be regarded, just as CGP 12177,
a weak partial agonist in the overall ranking of efficacy. Molecule poses of all molecules from the docking
calculations to at least one of the used structures can be found in the Supplemental PDB files.
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Discussion
This study investigated whether comparative docking to active (and inactive) conformations of the β2AR
could preferentially detect novel compounds with βAR agonist activity, rather than just detect antagonist
compounds. Moreover, we tried to determine the impact of using multiple β2ARactive structures and how to
best aggregate the individual rankings.
Molecule selection based on docking ranks. Since different approaches were used to retrieve potential
ligands with agonistic action from the ranked lists of each docking calculation in the present work, we can
evaluate each strategy in terms of the number of agonists retrieved. The initial hypothesis was that agonists
would be ranked higher in docking calculations against the β2ARactive than the β2ARinactive. This assumption
held true in retrospective studies. Somewhat unexpectedly, however, the selective reranking carried out in
this work did not yield molecules that we considered worth testing in the prospective docking. Despite this
low abundance of favourably interacting compounds, we still chose two smaller derivatives of compounds
emerging from this ranking. All additional compounds tested here were either selected from the individual
ranked lists of the docking calculations to the two β2ARactive (PDB IDs 3SN6 and 4LDL) or from the dual
reranking taking into account the ranked lists of both of these docking calculations (cf. equation 2).
In our hands, this dual reranking resulted not only in a very high hit rate, but also in a high number
of favourably interacting molecule poses in general. Our results therefore suggest that the most fruitful
approach to retrieve agonists are docking calculations to more than one structure in an active conformation,
aggregating the lists to identify those molecules that are ranked highly in both docking calculations. Turning
this around, and somewhat in contrast to our initial assumptions, a high agonist hit rate does not require
the comparison of docking calculations against β2ARactive and β2ARinactive structures.
The comparison to the retrospective docking calculations of known β2AR ligands suggests that our prospective
findings are echoed in the relative enrichments of agonists and antagonists over computer-matched decoys
and that such retrospective calculations could be used to indicate a priori which reranking scheme might
work best.
Closer evaluation of the molecule poses in the β2ARactive and the β2ARinactive, respectively, shows that
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orientations are similar, but that the molecule poses in the β2ARactive result, on average, in a higher number of
favourable interactions between receptor and molecule. We suggest that this fact can be used as an additional
criterion during pose evaluation: While poses of agonists obtained from docking calculations to the β2ARactive
should be reproducible in terms of general orientation in docking calculations to the β2ARinactive (since the
bigger pocket of the β2ARinactive should leave enough space), the interactions can allow differentiation (see
Fig. 5 for an overlay of all four used crystal structures).
We note that one agonist with significantly lower efficacy (8) from the primary screen was chosen from the
ranked list of a docking calculation to the inactive conformation structure 2RH1. The fact that 8 does not
find a favorable pose in the β2ARactive while it is a partial agonist leads to the conclusion that in certain
cases the discovery of bulky ligands from a docking calculation to the β2ARactive might be hampered by the
rigid conformation used during the calculation. A complementary docking calculation to the β2ARinactive
can be helpful here but also includes the risk of incorrect predictions, as statistically a favourable rank in
the β2ARinactive but not in the β2ARactive would be taken to indicate an antagonist or inverse agonist. That
the discovery of this agonist from a β2ARinactive structure is an exception is supported by the fact that none
of the ligands discovered in our earlier studies docking to a β2ARinactive were agonists. (Kolb et al., 2009;
Schmidt et al., 2017)
Pharmacological evaluation. Of the 27 compounds chosen from the docking screens for pharmacological
evaluation, 10/27 (37%) were found to be agonists of the β2AR, and most also of the β1AR, which we used to
evaluate the selectivity of the compounds. Importantly, all of these responses were demonstrated to occur at
the β2AR and β1AR, respectively, because all responses were inhibited by selective antagonists and there were
no responses in the parent CHO-CRE-SPAP cells without the transfected receptors. As for many agonists,
the affinity of these compounds for the β2AR and β1AR was relatively low. (Baker, 2010) However, for all
compounds that were found to have measureable binding, we found agonist activity, too.
Whilst it is easy to rank ligands in order of the direct measure of affinity, establishing a ligand’s intrinsic
efficacy is substantially harder, as there is no single direct pharmacological measure of intrinsic efficacy. One
simple way to be able to compare the intrinsic efficacy of compounds is to use an efficacy ratio — comparing
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the EC50 with the KD for the same compound, when all compounds are examined in parallel under identical
conditions. (Baker, 2010) Here it can be seen that cimaterol is the compound with the highest intrinsic efficacy
at both receptors (Table 2). As expected, denopamine had higher intrinsic efficacy at the β1AR than the β2AR
and salbutamol at the β2AR than the β1AR. (Baker, 2010) Of the novel agonists, 1 was the compound with the
highest intrinsic efficacy at both the β1AR and β2AR, followed by 2. Of note, none of the derivatives from the
analogue search was more active than the parent compounds. By the same measure, compound 1, the most
active molecule, has a similar intrinsic efficacy as salmeterol, a long-acting β2AR-agonist widely used in the
treatment of asthma and COPD. Thus, our approach of docking compounds to different active structures in
order to find novel compounds with agonism was able to discover novel compounds with sufficient agonism to
be potentially clinically useful. However, interestingly, this approach detected compounds of medium efficacy,
and not novel compounds with very high efficacy (such as catecholamines, fenoterol, or even cimaterol or
salbutamol (Baker, 2010)).
Structure-Activity Relationship. Several of the agonist compounds (1-7, 9, 11, 12) have rather similar
chemical structures and sometimes differ only by one substituent. This allows Structure-Activity Relationship
(SAR) conclusions to be drawn. Most compounds feature fluorine atoms at different positions on the aromatic
moiety closest to the hydroxyl-group of the β-hydroxy-amine. An additional fluorine atom in para position
(6 compared to 5) had essentially no effect on affinity and intrinsic efficacy. In meta position, an additional
fluorine atom (1 compared to 2), however, leads to increased binding affinity. As expected, the potency (EC50)
is also increased, leading to an almost unchanged intrinsic efficacy. The strongest effect on the efficacy can
be seen for the ortho position. Moving the ortho-fluorine atom (1) to the para-position (12) had no effect on
affinity, but did reduce the efficacy ratio (especially for the β2AR; from 1.76 to 1.05, Table 2). Exchanging
the fluorine for a chlorine in ortho position (3 compared to 4) results in almost unchanged affinity and pEC50
values. Of note, however, this exchange to a chlorine atom results in a higher % maximum response for the
β2AR (79% for 4 to 95% for 3) while it results in a lower % maximum response for the β1AR (60% for 4 to
33% for 3). This increase can likely be explained by the ability of chlorine to form stronger halogen bonds
than fluorine. This could result in a stabilisation of a more active conformation of the receptor. Considering
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the difference in responses at the β2AR and the β1AR, an interaction of the substituent in ortho position
with the protein seems likely. The most plausible candidate is Y3087.35 in TM VII (distances of 2.5-4 A˚
between the ortho substituents of the various ligands and the oxygen of the hydroxyl-group of Y3087.35 in
the respective energy-minimised docking poses), which is only present in the β2AR (it is a Phenylalanine in
the β1AR).
Finally, the comparison of 2 and 14 indicates that removing the hydroxyl group and introducing an ether in
the alkylic chain between aromatic moiety and secondary amine results in abolishment of binding.
In summary, multi-conformation docking screens appear as a productive strategy to identify novel molecules
with agonism similar to that of clinically used drugs. While the consideration of the ranks of each molecule in
the docking calculation against the β2ARinactive was not essential, comparison of the poses oftentimes helped
in deciding whether or not a particular molecule was likely an agonist or not. The specific conformations
elucidated in the crystallographically determined receptor structures appear to be sufficient to enrich agonists,
i.e. that “function follows form”. Our study also demonstrated that information is added with new structures
and that a dual reranking considering ranking lists of docking calculations to β2ARactive leads to the largest
number of agonists.
Last, but not least, we identified novel agonists for the β2AR featuring a previously undescribed pyrazole
moiety and intrinsic efficacies on par with clinically used drugs. Several derivatives were explored during
this project, revealing insights into their SAR. Docking calculations thus once again yielded a novel chemo-
type, (Sabio et al., 2008; Kolb et al., 2009; Weiss et al., 2013; Schmidt et al., 2017) particularly remarkable
for a target as well-explored as the β2AR.
While our findings should be readily transferable to other class A GPCRs with similarly successful results,
this approach could at the moment be more difficult when targeting GPCRs from other classes due to the
smaller number of available crystal structures. Yet, with structures appearing at the rate that they currently
do, this is an issue that will rapidly disappear in the future.
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Legends for Figures
Figure 1: Schematic representation of the docking calculations of molecules to the β2ARactive (PDB IDs
4LDL, 3SN6) and the β2ARinactive (PDB IDs 3NY9, 2RH1) and the obtained four different ranking lists of
molecules. The IDs of the selected molecules are given and marked in white text if found to be agonists
whereas those with names in black text did not interact with either the β2AR or the β1AR. No antagonists
(i.e. molecules that bind to the receptor but do not stimulate a response) were identified.
Figure 2: Dose-response curves for competition binding and functional assay results for compound 1. (A,B)
Whole cell competition binding with 3H-CGP 12177 in (A) CHO-β1AR cells and (B) CHO-β2AR cells. Bars
represent total and non-specific binding. Concentration of the radioligand was 0.77 nM for both experi-
ments. (C,D) CRE-SPAP production in (C) CHO-β1AR cells in response to 1 in the presence and absence
of CGP 20712A and in (D) CHO-β2AR cells in response to 1 in the presence and absence of ICI 118551.
Bars represent basal CRE-SPAP production or production in response to 10 μM isoprenaline or (C) 10 nM
CGP 20712A or (D) 3 nM ICI 118551. (A-D) Data points are mean ± sem of triplicates and the experiments
are representative for (A) 5, (B) 5, (C) 8 and (D) 7 seperate experiments.
Figure 3: ROC plots of known ligand and decoy docking calculations after (A) dual reranking of the ranking
lists of the docking calculations to β2ARactive 3SN6 and 4LDL and (B) after selective reranking of the ranking
lists of the docking calculations to β2ARactive 3SN6 vs. β2ARinactive 3NY9. Enrichment of known actives over
decoys was calculated treating only antagonists (blue curve), only agonists (orange curve) or all ligands
(green curve) as actives. Numbers represent the area under the curve and the dotted line indicates random
enrichment.
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on October 17, 2019 as DOI: 10.1124/mol.119.117515
 at A
SPET Journals on O
ctober 17, 2019
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL # 117515 30
Figure 4: (A) Molecule pose of 1 from the docking calculation to the β2ARactive structure 3SN6. The
molecule forms interactions with residues D1133.32 and N3127.39. (B) Molecule pose of 8 from the docking
calculation to the β2ARinactive structure 2RH1. The molecule is interacting with D1133.32 , probably also
with N2936.55 and N3127.39. It stretches up towards ECL2 and is too bulky to fit into the smaller cavity of
the β2ARactive.
Figure 5: Overlay of the β2AR structures used in this work as prepared for the docking calculations.
Two structures in active conformations (3SN6 [orange] and 4LDL [magenta]) and two structures in inactive
conformations (3NY9 [cyan] and 2RH1 [green]) are compared. Differences of side chain positions between all
structures as well as between active conformations and inactive conformations can be observed. Although
these changes can be considered small, they still allow to distinguish agonists and antagonists in docking
calculations. (A) Side view of the orthosteric binding pocket. Residues that are involved in ligand binding
are highlighted (compare also Fig. 4). (B) Top view from the extracellular side of the receptor into the
orthosteric binding pocket. The same residues as in (A) are highlighted as sticks as well as residue Y3087.35,
which was not shown in (A) for clarity. Other residues are shown in line representation in this panel to give
a better impression of overall differences of the side chain positions in the binding pocket.
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Tables
Table 1: log KD values (affinity) of known and novel compounds detected through docking to the β2AR
structures in active and inactive conformations, as determined from 3H-CGP 12177 whole cell binding (mean
±SEM of n separate experiments). Compounds are in order of efficacy ratio at the β2AR (a measure of
intrinsic efficacy, see text and Table 2).
Compound Structure β1AR logKD n β2AR logKD n
Literature known reference compounds.
Cimaterol -6.4±0.1 3 -7.1±0.1 3
Salbutamol -5.0±0.1 5 -6.3±0.1 5
Salmeterol -5.7±0.0 7 -9.1±0.0 7
Denopamine -6.0±0.1 5 -5.3±0.1 5
CGP 12177 -9.4±0.0 3 -9.6±0.1 3
CGP 20712A -8.6±0.2 6 -5.8±0.1 8
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ICI 118551 -6.8±0.1 7 -9.3±0.1 7
Compounds chosen from docking calculations.
1 -6.3±0.0 5 -6.3±0.1 5
2 -6.0±0.0 5 -5.9±0.1 5
3 -5.0±0.1 5 -5.6±0.0 5
4 -5.5±0.1 5 -5.9±0.1 5
5 -5.6±0.0 5 -5.4±0.1 5
6 -5.8±0.0 6 -5.7±0.0 5
7 -5.8±0.0 5 -5.9±0.0 5
8 -5.0±0.0 6 -6.1±0.1 6
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9 -5.0±0.1 5 IC50 > −4 5
10 no binding 5 IC50 > −4 5
11a -5.3±0.0 5 -5.3±0.0 5
12a -6.2±0.0 6 -6.1±0.1 6
14a IC50 > −4 6 IC50 > −4 6
22 IC50 > −4 5 IC50 > −4 6
25 no binding 5 IC50 > −4 5
26 no binding 5 IC50 > −4 5
a Molecules selected from secondary screen.
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Comparative docking to distinct G protein-coupled receptor
conformations exclusively yields ligands with agonist efficacy
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Supplemental assay: Preliminary cAMP accumulation assay
Supplemental Method For a preliminary screen for agonistic activity of the selected compounds, the GS
assay kit from Cisbio was used. HEK293T cells expressing the β2AR endogenously were grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum, 2 mM l-glutamine, 100 U/mL Peni-
cillin and 100 μg/mL Streptomycin at 37◦C and 5% CO2.
The assay protocol provided by Cisbio was optimised to yield the optimal assay window for the used system.
Cells were suspended in modified tyrode buffer (10 mM HEPES, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl,
146 mM NaCl, 5.5 mM Glucose; pH=7.4) supplemented with 0.5 mM IBMX at a concentration of 1400 cells/μL
and 5 μL cell suspension transferred to the wells of a 384-well plate.
To measure agonism, 5 μL buffer or compound dilution in buffer (two times the final concentration) were
added to each well and incubated at room temperature for 10 min. Detection reagents were added as recom-
mended by Cisbio (5 μL per well of one time dilution detection reagent in the provided lysis buffer). The plates
were then incubated for 1 h at room temperature in the dark, before they were read on a Tecan Spark 20M
plate reader. Isoprenaline dose-response curves were included in each measurement as a reference as well as
measurements to account for basal activity and background fluorescence of the detection reagents.
To determine antagonism, the protocol was varied slightly. To each well containing the cell suspension, 3 μL
buffer or compound dilution in buffer (3.3 times the final concentration) were added and incubated at room
temperature for 10 min. After this incubation, 2 μL buffer or isoprenaline (final concentration in the well:
80 nM) were added and the plate was incubated for another 10 min at room temperature. Detection reagents
were then added as recommended by Cisbio and the plates were incubated at room temperature in the dark
for 1 h. After 1 h, the plate was read on a Tecan Spark 20M plate reader. Propranolol was used as a reference
compound in each measurement and results were adjusted for basal activity and background fluorescence of
the detection reagents. The resulting data was analysed as described in the Cisbio assay protocol and plotted
using GraphPad Prism 7.
Supplemental Results Although the assay showed only low sensitivity and could therefore not be used
to determine reliable EC50 values, it was used to gather qualitative information. The two ligands with the
MOL # 117515 Supplemental Data 3
highest efficacy ratio towards the β2AR, 1 and 2, were identified as agonists with this assay (see Supplemental
Figure 1). All of the other agonists that were identified in the CRE-SPAP assays showed increased HTRF
ratios for the higher concentrations in the antagonist assay setup.
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Supplemental Figure 1: Dose-response curves of some of the tested compounds in a preliminary cAMP ac-
cumulation assay. (A) Compounds 1 and 2 showed agonistic activity in the assay. Responses were normalised
to the maximum response of Isoprenaline. (B) Compounds 4, 3 and 8 showed increasing HTRF ratios for
higher concentrations in the antagonist assay setup. Propranolol was measured as a reference compound.
Data points are mean ± sem of duplicates in (A) 2 and (B) 1 seperate experiment.
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Supplemental Figure 2: ROC plots of known ligand and decoy docking calculations to β2ARactive (A)
3SN6 and (B) 4LDL. Enrichments were calculated using only antagonists (blue curve), only agonists (orange
curve) or all ligands (green curve) as actives. Numbers are area under the curve and the dotted line represents
random enrichment.
Supplemental Tables
Supplemental Table 1: SMILES and vendor information of all tested molecules.
Mol SMILES string Vendor Vendor ID ZINC ID
1 CC(Cn1cccn1)[NH2+]CC(c2cc(ccc2F)F)O Enaminea Z1139549933 C49075870
2 CC(Cn1cccn1)[NH2+]CC(c2ccccc2F)O Enaminea Z1139549920 C49075832
3 c1ccc(cc1)CC[NH2+]CC(c2ccccc2Cl)O Enaminea BBV-32195129 C32122137
4 c1ccc(cc1)CC[NH2+]CC(c2ccccc2F)O Enaminea BBV-32188060 C32110999
5 Cc1cnn(c1)CC(C)[NH2+]CC(c2cccc(c2)F)O Enaminea Z1139457046 C69489460
6 Cc1cnn(c1)CC(C)[NH2+]CC(c2ccc(c(c2)F)F)O Enaminea Z1139457054 C69534697
7 Cc1cccc(c1)C(C[NH2+]C(C)Cn2cc(cn2)Br)O Enaminea Z1582993358 C90520132
8 CC(C)[NH2+]CC(c1cccc(c1)OCc2ccccc2)O Enaminea Z1597907783 C32131959
9 Cc1c(c(n(n1)CC[NH2+]C(C)Cc2ccccc2F)C)Cl ChemBridged 75024249 C65461465
10 COc1cccc(c1)C(C[NH2+]C2Cc3cccc(c3OC2)OC)O Enaminea Z1823958433 C97105309
11 CC(NCC](O)c1ccccc1F)C(C)n1cccn1 Enaminea Z1143054162 C72269793
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12 CC(Cn1cccn1)NCC(O)c1ccc(F)c(F)c1 Enaminea Z1139549938 C49075899
13 OC(CN1CCCC1Cn1cccn1)c1cc(F)ccc1F Enaminea Z1139479667 C71875670
14 CC(Cn1cccn1)NCCOc1ccccc1F Enaminea Z414797082 C69387511
15 CC(NCCn1cccn1)c1cc(F)ccc1F Enaminea Z1139746195 C42538939
16 c1ccnc(c1)NC(=O)COc2ccc(cc2)C(=O)N Enaminea Z848936154 C49105831
17 CC(C(=O)NCCc1ccc(cc1)F)[NH3+] FCH Groupb FCG1450162145 C19502698
18 c1ccc2c(c1)nc(o2)C[NH2+]C3CCCN(C3)c4cccnn4 Enaminea Z1139245547 C69872322
19 COc1ccc(cc1)CCNC(=O)C(CC(=O)[O-])[NH3+] Enaminea BBV-39452572 C83483625
20 CC(Cn1cc(cn1)Br)[NH2+]CC(C)(c2ccsc2)O Enaminea Z1441405249 C95968346
21 CC(CC(=O)OC)[NH2+]CC1Cc2ccccc2O1 Enaminea BBV-32282913 C38009848
22 c1cc(cnc1)c2c(c[nH]n2)C[NH2+]Cc3cc4cc(ccc4s3)F Enaminea Z2241129897 C65595055
23 CC(Cn1cccn1)[NH2+]Cc2cn3cc(cc(c3n2)Cl)Cl Enaminea Z1139744745 C69389875
24 c1cc(cnc1)c2c(c[nH]n2)CNCc3ccc(nc3)n4ccnc4 Enaminea Z2241113193 C97159292
25 c1cc(ccc1C[NH2+]Cc2c[nH]nc2c3ccc(cc3)F)n4cncn4 UORSYc PB1135242967 C78552850
26 Cc1ccc(o1)c2c(c[nH]n2)C[NH2+]Cc3cn4cc(ccc4n3)Cl Enaminea Z2241115638 C97159595
27 CC(C(=O)Nc1ccc(c(c1)C(F)(F)F)Cl)[NH2+]C Enaminea Z44508089 C55421527
a SIA Enamine, Vestienas iela 2B, LV-1035 Riga, LATVIA
b FCH Group, PO Box 438, 14017 Chernigiv, UKRAINE
c Ukrorgsyntez Ltd., PO Box 59, 02002 Kyiv, UKRAINE
d ChemBridge Corporation, 11199 Sorrento Valley Rd., Suite 206, San Diego, CA 92121, USA
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Supplemental Table 2: Compounds selected from the docking calculations that did not show affinity to
either the β1AR or the β2AR. These molecules did not induce agonist activity, either.
Mol Structure β1AR log KD n β2AR log KD n
13a no binding 5 no binding 5
15a* no binding 5 no binding 5
16 no binding 5 no binding 5
17 no binding 5 no binding 5
18 no binding 5 no binding 5
19 no binding 5 no binding 5
20 no binding 5 no binding 5
21 no binding 5 no binding 5
23 no binding 5 no binding 5
MOL # 117515 Supplemental Data 7
24 no binding 5 no binding 5
27 no binding 5 no binding 5
a Molecules chosen from secondary screen.
Supplemental Table 3: Similarity of tested molecules to ligands of the β2AR in ChEMBL bioactivity
dataset. ChEMBL ID and Smiles of most similar molecule as well as Tanimoto ECFP4 coefficient are listed
(first entry of the result table if several molecules with the same smilarity were found).
Mol ChEMBL ID Smiles Tanimoto
1 CHEMBL16476 CC(C)NCC(O)c1ccc2ccccc2c1 0.25
2 CHEMBL1902627 CC(C)NCC(O)c1ccccc1Cl 0.31
3 CHEMBL599896 Cl.CC(CCc1ccccc1)NCC(O)c2cccc(c2)[N+](=O)[O-] 0.41
4 CHEMBL599896 Cl.CC(CCc1ccccc1)NCC(O)c2cccc(c2)[N+](=O)[O-] 0.41
5 CHEMBL327122 CC(C)NCC(O)c1cccc(O)c1 0.32
6 CHEMBL321468 CC(C)NCC(O)c1ccc(O)c(CO)c1 0.28
7 CHEMBL327122 CC(C)NCC(O)c1cccc(O)c1 0.32
8 CHEMBL599896 Cl.CC(CCc1ccccc1)NCC(O)c2cccc(c2)[N+](=O)[O-] 0.47
9 CHEMBL1159723 CCCc1ccccc1OCC(O)CNC(C)C 0.26
10 CHEMBL26183 COc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(Cl)c3)c[nH]c12 0.36
11 CHEMBL1902627 CC(C)NCC(O)c1ccccc1Cl 0.45
12 CHEMBL16476 CC(C)NCC(O)c1ccc2ccccc2c1 0.39
13 CHEMBL1723653 Cc1ncc(CN2CCCC(C2)C(=O)Nc3ccc(cc3)c4cccc(F)c4)s1 0.24
14 CHEMBL1626224 CC(O)CNCCOc1ccccc1c2ccccc2 0.38
15 CHEMBL16476 CC(C)NCC(O)c1ccc2ccccc2c1 0.24
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16 CHEMBL1577023 Cc1ccc(OCC(=O)Nc2ccc(cc2)c3oc4cccnc4n3)cc1 0.39
17 CHEMBL24 CC(C)NCC(O)COc1ccc(CC(=O)N)cc1 0.31
18 CHEMBL2441621 C1CN(CCN1)c2ccnc3ccccc23 0.30
19 CHEMBL3099658 COc1ccc(CCNC[C@@H](O)c2cc(O)cc(O)c2)cc1 0.37
20 CHEMBL1159717 CC(C)(C)NCC(O)c1ccccc1Cl 0.18
21 CHEMBL1200586 Cl.CCCNC(C)C(=O)Nc1ccccc1C 0.28
22 CHEMBL1573444 CN(Cc1ccccc1F)c2nc(nc3ccccc23)c4cccnc4 0.31
23 CHEMBL531401 CC(Oc1ccc(Cl)cc1Cl)c2onc(n2)c3ccc(NC(=O)c4occc4)cc3 0.21
24 CHEMBL3099899 COc1ccc(CNC(=O)c2cc(cnc2c3cccnc3)c4cc(Cl)cc(Cl)c4)cc1OC 0.30
25 CHEMBL305558 O[C@@H](CNCCc1ccc(NS(=O)(=O)c2ccc(cc2)n3ncc(n3) 0.33
c4ccc(F)cc4)cc1)c5cccnc5
26 CHEMBL252766 CSc1ccc2nc(cn2c1)c3ccc(cc3)N(C)C 0.27
27 CHEMBL1439691 CCN(CC)S(=O)(=O)c1cc(NC(=O)C2=COCCO2)ccc1Cl 0.26
Supplemental Table 4: Similarity of tested molecules to ligands of any adrenergic receptor in the ChEMBL
bioactivity dataset. ChEMBL ID and smiles of most similar molecule as well as Tanimoto ECFP4 coefficient
are listed (first entry of the result table if several molecules with the same smilarity were found).
Mol ChEMBL ID Smiles Tanimoto
1 CHEMBL15303 CC(C)NCC(O)COc1ccccc1Cn2cccn2 0.33
2 CHEMBL15303 CC(C)NCC(O)COc1ccccc1Cn2cccn2 0.42
3 CHEMBL599896 Cl.CC(CCc1ccccc1)NCC(O)c2cccc(c2)[N+](=O)[O-] 0.41
4 CHEMBL7156 OC(CNCCNC(=O)Cc1ccccc1)COC(=O)c2ccccc2F 0.42
5 CHEMBL327122 CC(C)NCC(O)c1cccc(O)c1 0.32
6 CHEMBL62072 CNCC(O)c1ccc(F)c(O)c1 0.31
7 CHEMBL25724 CC(Cc1c[nH]c2cc(C)ccc12)NCC(O)c3cccc(Cl)c3 0.32
8 CHEMBL599896 Cl.CC(CCc1ccccc1)NCC(O)c2cccc(c2)[N+](=O)[O-] 0.47
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9 CHEMBL3588911 CC(C)NCc1nccn1Cc2ccccc2C 0.30
10 CHEMBL2153551 Cl.COc1cccc(OC)c1OCCNC[C@H]2COc3cccc(O)c3O2 0.36
11 CHEMBL1902627 CC(C)NCC(O)c1ccccc1Cl 0.45
12 CHEMBL16476 CC(C)NCC(O)c1ccc2ccccc2c1 0.39
13 CHEMBL1767149 CN1CCC[C@@H]1CN2N=C(Cc3ccc(F)c(F)c3)c4ccccc4C2=O 0.33
14 CHEMBL15303 CC(C)NCC(O)COc1ccccc1Cn2cccn2 0.49
15 CHEMBL15303 CC(C)NCC(O)COc1ccccc1Cn2cccn2 0.34
16 CHEMBL1577023 Cc1ccc(OCC(=O)Nc2ccc(cc2)c3oc4cccnc4n3)cc1 0.39
17 CHEMBL6863 CC(C)NCC(O)COC(=O)c1ccc(F)cc1 0.38
18 CHEMBL18772 C1CN(CCN1)c2ccc3ccccc3n2 0.31
19 CHEMBL3099658 COc1ccc(CCNC[C@@H](O)c2cc(O)cc(O)c2)cc1 0.37
20 CHEMBL371300 C[C@H](N)Cn1ncc2ccc(O)cc12 0.23
21 CHEMBL1203102 Cl.COC(=O)c1cc(ccc1O)C(O)CNCC2COc3ccccc3O2 0.31
22 CHEMBL1573444 CN(Cc1ccccc1F)c2nc(nc3ccccc23)c4cccnc4 0.31
23 CHEMBL1327 OC(Cn1ccnc1)c2ccc(Cl)cc2Cl 0.30
24 CHEMBL3588905 C(NCc1c[nH]c(n1)c2ccccc2)c3cccnc3 0.42
25 CHEMBL305558 O[C@@H](CNCCc1ccc(NS(=O)(=O)c2ccc(cc2)n3ncc(n3) 0.33
c4ccc(F)cc4)cc1)c5cccnc5
26 CHEMBL351483 CC1=C(CCN2CCc3oc4ccccc4c3C2)C(=O)N5C=C(Cl)C=CC5=N1 0.30
27 CHEMBL101340 FC(F)(F)c1ccc(Cl)c(NC2=NCCN2)c1 0.31
Supplemental Data
Molecule poses from docking calculations for all tested molecules are available as PDB files in at least one
of the structures 3SN6, 4LDL or 2RH1 as used for the docking calculations. A list of the PDB files can be
found below sorted by compound number.
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Compound 1: 3SN6 cmpd-01.pdb; 4LDL cmpd-01.pdb
Compound 2: 3SN6 cmpd-02.pdb; 4LDL cmpd-02.pdb
Compound 3: 3SN6 cmpd-03.pdb; 4LDL cmpd-03.pdb
Compound 4: 3SN6 cmpd-04.pdb; 4LDL cmpd-04.pdb
Compound 5: 3SN6 cmpd-05.pdb; 4LDL cmpd-05.pdb
Compound 6: 3SN6 cmpd-06.pdb; 4LDL cmpd-06.pdb
Compound 7: 3SN6 cmpd-07.pdb; 4LDL cmpd-07.pdb
Compound 8: 2RH1 cmpd-08.pdb; 3SN6 cmpd-08.pdb; 4LDL cmpd-08.pdb
Compound 9: 4LDL cmpd-09.pdb
Compound 10: 3SN6 cmpd-10.pdb; 4LDL cmpd-10.pdb
Compound 11: 3SN6 cmpd-11.pdb
Compound 12: 3SN6 cmpd-12.pdb
Compound 13: 3SN6 cmpd-13.pdb
Compound 14: 3SN6 cmpd-14.pdb
Compound 15: 3SN6 cmpd-15.pdb
Compound 16: 3SN6 cmpd-16.pdb
Compound 17: 3SN6 cmpd-17.pdb
Compound 18: 3SN6 cmpd-18.pdb
Compound 19: 3SN6 cmpd-19.pdb
Compound 20: 3SN6 cmpd-20.pdb
Compound 21: 3SN6 cmpd-21.pdb; 4LDL cmpd-21.pdb
Compound 22: 3SN6 cmpd-22.pdb; 4LDL cmpd-22.pdb
Compound 23: 3SN6 cmpd-23.pdb; 4LDL cmpd-23.pdb
Compound 24: 3SN6 cmpd-24.pdb; 4LDL cmpd-24.pdb
Compound 25: 4LDL cmpd-25.pdb
Compound 26: 4LDL cmpd-26.pdb
Compound 27: 4LDL cmpd-27.pdb
